CJC-1295 vs Ipamorelin
Research Verdict
Neither compound has a universal evidence advantage. Research distinction: When sustained IGF-1 elevation is the research goal and the non-pulsatile GH profile is acceptable vs. ipamorelin goals.
Quick Answers
Which is better, CJC-1295 or Ipamorelin?
Neither compound has a universal evidence advantage. Research distinction: When sustained IGF-1 elevation is the research goal and the non-pulsatile GH profile is acceptable vs. ipamorelin goals.
What is the key difference between CJC-1295 and Ipamorelin?
CJC-1295 (with DAC) produces non-physiological continuous GH elevation due to its 8-day half-life; ipamorelin produces discrete GH pulses more closely mimicking physiological secretion. The combination is theorized to be synergistic (GHRH + GHRP act on different pituitary receptors), but no RCT has tested the combination specifically.
Evidence Comparison
CJC-1295 (with DAC) has Phase 2 human data (Ionescu & Frohman 2006, J Clin Endocrinol Metab) showing sustained GH and IGF-1 elevation. Ipamorelin has Phase 2 data from Helsinn's post-operative ileus trial but less published GH-secretagogue characterization in humans. Both are investigational compounds with no clinical approval for off-label GH enhancement.
Evidence Context Favoring CJC-1295
When sustained IGF-1 elevation is the research goal and the non-pulsatile GH profile is acceptable.
Evidence Context Favoring Ipamorelin
When preserving pulsatile GH rhythm is a priority, or when cortisol/prolactin neutrality is important (ipamorelin's key differentiator).
Side-by-Side Snapshot
| Evidence grade | CJC-1295: Level B Ipamorelin: Level B |
|---|---|
| Research status | CJC-1295: Phase 2 Ipamorelin: Phase 2 |
| Primary category | CJC-1295: Growth Hormone Ipamorelin: Growth Hormone |
| Cited studies | CJC-1295: 1 Ipamorelin: 3 |